ID

35866

Beschreibung

Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01992952

Link

https://clinicaltrials.gov/show/NCT01992952

Stichworte

Versionen (1)
  1. 29.03.19 29.03.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

29. März 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Estrogen Receptor Positive Breast Cancer NCT01992952

Englisch

Eligibility Estrogen Receptor Positive Breast Cancer NCT01992952

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
post-menopausal women
Beschreibung

Postmenopausal state

Datentyp

boolean

Alias
UMLS CUI [1]
C0232970
life expectancy 3 months
Beschreibung

Life Expectancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0023671
histological confirmation of er+ breast cancer
Beschreibung

Oestrogen receptor positive breast cancer

Datentyp

boolean

Alias
UMLS CUI [1]
C2938924
clinical or histological confirmation of metastatic or locally advanced disease not amenable to surgical resection
Beschreibung

Neoplasm Metastasis Inappropriate Excision | Advanced disease Locally Inappropriate Excision

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C1548788
UMLS CUI [1,3]
C0728940
UMLS CUI [2,1]
C0679246
UMLS CUI [2,2]
C1517927
UMLS CUI [2,3]
C1548788
UMLS CUI [2,4]
C0728940
measurable or non-measurable disease
Beschreibung

Measurable Disease | Non-Measurable Lesion

Datentyp

boolean

Alias
UMLS CUI [1]
C1513041
UMLS CUI [2]
C1334988
adequate bone marrow, renal and hepatic function
Beschreibung

Bone Marrow function | Renal function | Liver function

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232741
eastern cooperative oncology group (ecog) performance status < or equal to 2
Beschreibung

ECOG performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
progressive disease whilst receiving an aromatase inhibitor (ai) for metastatic breast cancer (mbc)
Beschreibung

Progressive Disease | Aromatase Inhibitor Secondary malignant neoplasm of female breast

Datentyp

boolean

Alias
UMLS CUI [1]
C1335499
UMLS CUI [2,1]
C0593802
UMLS CUI [2,2]
C0346993
relapsed with metastatic disease whilst receiving an ai in adjuvant setting
Beschreibung

Metastatic/Recurrent Disease | Aromatase Inhibitor Adjuvant therapy

Datentyp

boolean

Alias
UMLS CUI [1]
C1334739
UMLS CUI [2,1]
C0593802
UMLS CUI [2,2]
C0677850
up to 3 prior lines endocrine therapy for mbc
Beschreibung

Hormone Therapy Quantity Secondary malignant neoplasm of female breast

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0279025
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0346993
up to 1 line of chemotherapy in the metastatic setting
Beschreibung

Chemotherapy Quantity Neoplasm Metastasis

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0027627
patient willing to donate archival tumour sample
Beschreibung

Tumor tissue sample Donation

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0475358
UMLS CUI [1,2]
C0680854
patient willing to donate baseline blood sample
Beschreibung

Blood specimen Donation

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0178913
UMLS CUI [1,2]
C0680854
adequate bone marrow and organ function
Beschreibung

Bone Marrow function | Organ function

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [2]
C0678852
suitable for further endocrine therapy
Beschreibung

Suitable Hormone Therapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C3900053
UMLS CUI [1,2]
C0279025
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous treatment with fulvestrant or pi3k/mtor(mammalian target of rapamycin )/akt inhibitor therapy
Beschreibung

fulvestrant | Phosphatidylinositide 3-Kinase Inhibitor | mTOR Inhibitor | AKT1 gene Inhibitor | AKT2 gene Inhibitor | AKT3 gene Inhibitor

Datentyp

boolean

Alias
UMLS CUI [1]
C0935916
UMLS CUI [2]
C1519050
UMLS CUI [3]
C2746052
UMLS CUI [4,1]
C0812228
UMLS CUI [4,2]
C1999216
UMLS CUI [5,1]
C0812230
UMLS CUI [5,2]
C1999216
UMLS CUI [6,1]
C1332074
UMLS CUI [6,2]
C1999216
clinically significant abnormalities in glucose metabolism
Beschreibung

Glucose metabolism abnormal

Datentyp

boolean

Alias
UMLS CUI [1]
C1142273
rapidly progressive visceral disease not suitable for further endocrine therapy
Beschreibung

Disease Visceral Rapidly progressive | Hormone Therapy Inappropriate

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0442045
UMLS CUI [1,3]
C1838681
UMLS CUI [2,1]
C0279025
UMLS CUI [2,2]
C1548788
known brain or leptomeningeal metastases
Beschreibung

Metastatic malignant neoplasm to brain | Metastatic Malignant Neoplasm to the Leptomeninges

Datentyp

boolean

Alias
UMLS CUI [1]
C0220650
UMLS CUI [2]
C1704231
any co-existing medical condition precluding trial entry including significant cardiac disease (to be defined in the protocol)
Beschreibung

Comorbidity Study Subject Participation Status Excluded | Heart Disease Significant

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C2348568
UMLS CUI [1,3]
C0332196
UMLS CUI [2,1]
C0018799
UMLS CUI [2,2]
C0750502
concomitant medication unsuitable for combination with trial medication
Beschreibung

Pharmaceutical Preparations Inappropriate Combination Investigational New Drugs

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1548788
UMLS CUI [1,3]
C0205195
UMLS CUI [1,4]
C0013230
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Estrogen Receptor Positive Breast Cancer NCT01992952

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Postmenopausal state
Item
post-menopausal women
boolean
C0232970 (UMLS CUI [1])
Life Expectancy
Item
life expectancy 3 months
boolean
C0023671 (UMLS CUI [1])
Oestrogen receptor positive breast cancer
Item
histological confirmation of er+ breast cancer
boolean
C2938924 (UMLS CUI [1])
Neoplasm Metastasis Inappropriate Excision | Advanced disease Locally Inappropriate Excision
Item
clinical or histological confirmation of metastatic or locally advanced disease not amenable to surgical resection
boolean
C0027627 (UMLS CUI [1,1])
C1548788 (UMLS CUI [1,2])
C0728940 (UMLS CUI [1,3])
C0679246 (UMLS CUI [2,1])
C1517927 (UMLS CUI [2,2])
C1548788 (UMLS CUI [2,3])
C0728940 (UMLS CUI [2,4])
Measurable Disease | Non-Measurable Lesion
Item
measurable or non-measurable disease
boolean
C1513041 (UMLS CUI [1])
C1334988 (UMLS CUI [2])
Bone Marrow function | Renal function | Liver function
Item
adequate bone marrow, renal and hepatic function
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status < or equal to 2
boolean
C1520224 (UMLS CUI [1])
Progressive Disease | Aromatase Inhibitor Secondary malignant neoplasm of female breast
Item
progressive disease whilst receiving an aromatase inhibitor (ai) for metastatic breast cancer (mbc)
boolean
C1335499 (UMLS CUI [1])
C0593802 (UMLS CUI [2,1])
C0346993 (UMLS CUI [2,2])
Metastatic/Recurrent Disease | Aromatase Inhibitor Adjuvant therapy
Item
relapsed with metastatic disease whilst receiving an ai in adjuvant setting
boolean
C1334739 (UMLS CUI [1])
C0593802 (UMLS CUI [2,1])
C0677850 (UMLS CUI [2,2])
Hormone Therapy Quantity Secondary malignant neoplasm of female breast
Item
up to 3 prior lines endocrine therapy for mbc
boolean
C0279025 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0346993 (UMLS CUI [1,3])
Chemotherapy Quantity Neoplasm Metastasis
Item
up to 1 line of chemotherapy in the metastatic setting
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
Tumor tissue sample Donation
Item
patient willing to donate archival tumour sample
boolean
C0475358 (UMLS CUI [1,1])
C0680854 (UMLS CUI [1,2])
Blood specimen Donation
Item
patient willing to donate baseline blood sample
boolean
C0178913 (UMLS CUI [1,1])
C0680854 (UMLS CUI [1,2])
Bone Marrow function | Organ function
Item
adequate bone marrow and organ function
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0678852 (UMLS CUI [2])
Suitable Hormone Therapy
Item
suitable for further endocrine therapy
boolean
C3900053 (UMLS CUI [1,1])
C0279025 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
fulvestrant | Phosphatidylinositide 3-Kinase Inhibitor | mTOR Inhibitor | AKT1 gene Inhibitor | AKT2 gene Inhibitor | AKT3 gene Inhibitor
Item
previous treatment with fulvestrant or pi3k/mtor(mammalian target of rapamycin )/akt inhibitor therapy
boolean
C0935916 (UMLS CUI [1])
C1519050 (UMLS CUI [2])
C2746052 (UMLS CUI [3])
C0812228 (UMLS CUI [4,1])
C1999216 (UMLS CUI [4,2])
C0812230 (UMLS CUI [5,1])
C1999216 (UMLS CUI [5,2])
C1332074 (UMLS CUI [6,1])
C1999216 (UMLS CUI [6,2])
Glucose metabolism abnormal
Item
clinically significant abnormalities in glucose metabolism
boolean
C1142273 (UMLS CUI [1])
Disease Visceral Rapidly progressive | Hormone Therapy Inappropriate
Item
rapidly progressive visceral disease not suitable for further endocrine therapy
boolean
C0012634 (UMLS CUI [1,1])
C0442045 (UMLS CUI [1,2])
C1838681 (UMLS CUI [1,3])
C0279025 (UMLS CUI [2,1])
C1548788 (UMLS CUI [2,2])
Metastatic malignant neoplasm to brain | Metastatic Malignant Neoplasm to the Leptomeninges
Item
known brain or leptomeningeal metastases
boolean
C0220650 (UMLS CUI [1])
C1704231 (UMLS CUI [2])
Comorbidity Study Subject Participation Status Excluded | Heart Disease Significant
Item
any co-existing medical condition precluding trial entry including significant cardiac disease (to be defined in the protocol)
boolean
C0009488 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C0332196 (UMLS CUI [1,3])
C0018799 (UMLS CUI [2,1])
C0750502 (UMLS CUI [2,2])
Pharmaceutical Preparations Inappropriate Combination Investigational New Drugs
Item
concomitant medication unsuitable for combination with trial medication
boolean
C0013227 (UMLS CUI [1,1])
C1548788 (UMLS CUI [1,2])
C0205195 (UMLS CUI [1,3])
C0013230 (UMLS CUI [1,4])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video